Medicare coverage of Alzheimer’s drug Aduhelm may soon be dramatically limited. The CMS is asking for public comments before finalizing the decision. Last week,…
COVID-19 and Alzheimer’s share the same brain damage biomarkers. Blood samples reveal they accumulate at higher levels over a shorter period of time in…
It seems like, following the FDA’s controversial July 2021 approval of Biogen’s Alzheimer’s drug Aduhelm, everyone is mad at someone. Here are the main…
Early-onset Alzheimer’s may come with more severe behavioral symptoms than late-onset Alzheimer’s, a new study finds. Clinicians have suspected that people with early-onset Alzheimer’s,…
Scott Rose speaks about the memories he shared with his late wife Maureen Patrick-Rose, who was diagnosed with frontotemporal dementia and appendiceal cancer. Finding…
Aduhelm’s clinical trials shines a light on why representation is crucial in the search for effective Alzheimer’s treatments. The Food and Drug Administration’s (FDA)…
The Centers for Medicare and Medicaid Services will limit Aduhelm coverage to only participants in approved clinical trials. Major U.S. healthcare providers have refused…